AI-driven protein synthesis platform Tierra Biosciences has raised USD 11.4 million in a Series A funding round led by Material Impact with contributions from Prosus Ventures, In-Q-Tel (IQT), Hillspire, and others.
The funds will be used to reach a broader customer base and partner network, strengthen its AI data generation capabilities, and assemble a commercial team to grow sales.
Tierra Biosciences, formerly known as Synvitrobio, is a synthetic biology company that focuses on discovering and developing bio-based materials through its proprietary cell-free synthetic biology technology. The company's Tierra Protein Platform leverages automation and AI to facilitate the synthesis of custom proteins outside of living cells. The company has produced over 5,000 proteins to date offering a way to speed up the protein development process from months to weeks.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.